Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
Available information on pancreatic cancer was written at too high a level and contained inaccuracies regarding alternative therapies, a recent study has shown.
[Journal of Gastrointestinal Oncology] This research reviews the case history of a patient with stage IVB pancreatic adenocarcinoma initially treated with gemcitabine and erlotinib who stopped therapy after 3 months without achieving a response and was switched to a different and effective combination strategy.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
